Immune Checkpoint Inhibitors (ICIs) on Patients With Hepatitis B Virus Infection: A Promising Approach for Achieving HBsAg Loss

Authors

  • Dolvy Girawan Fellows of the Indonesian Society of Internal Medicine; Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin Hospital, Bandung

DOI:

https://doi.org/10.24871/27120261-2

Abstract

-

References

Velkov S, Ott JJ, Protzer U, Michler T. The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes. 2018;9:495.

Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143:963–973.

Höner Zu Siederdissen C, Rinker F, Maasoumy B, et al. Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis. 2016;214:1492–1497.

Rivino L, Le Bert N, Gill US, et al. Hepatitis B virus specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest. 2018;128:668–681.

Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology. 2014;146:1193–1207.

Mon HC, Lee PC, Chia CT, Huang YH. Effect of immune checkpoint inhibitors on patients with hepatitis B virus infection. J Chin Med Assoc. 2025;88:93–97.

Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138:30–50.

Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77:4911–4927.

Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687.

Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29–37.

Crawford A, Wherry EJ. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol. 2009;21:179–186.

Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.

Koksal AS, Toka B, Eminler AT, Hacibekiroglu I, Uslan MI, Parlak E. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Ann Oncol. 2017;28:3103–3104.

Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138:682–693.e1.

Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol. 2010;52:616–619.

Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71:900–907.

Qian J, Xie Y, Mao Q, Xie Q, Gu Y, Chen X, et al. A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally-suppressed, HBeAg-negative chronic hepatitis B patients. Hepatology. 2024. doi:10.1097/HEP.0000000000001006.

Tak WY, Chuang WL, Chen CY, Tseng KC, Lim YS, Lo GH, et al. Phase Ib/IIa randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB. J Hepatol. 2024;81:949–959.

Downloads

Published

2026-04-30

How to Cite

Girawan, D. (2026). Immune Checkpoint Inhibitors (ICIs) on Patients With Hepatitis B Virus Infection: A Promising Approach for Achieving HBsAg Loss. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 27(1), 1–2. https://doi.org/10.24871/27120261-2

Issue

Vol. 27 No. 1 (2026): VOLUME 27, NUMBER 1, April, 2026

Section

Editorial

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).